Jennifer R Grandis

List of Publications by Year
in descending order

Version: 2024-02-01

142 papers	12,565 citations	50244 46 h-index	26591 107 g-index
145 all docs	145 docs citations	145 times ranked	17784 citing authors

#	Article	IF	Citations
1	The Mutational Landscape of Head and Neck Squamous Cell Carcinoma. Science, 2011, 333, 1157-1160.	6.0	2,225
2	Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology, 2018, 15, 234-248.	12.5	1,789
3	Head and neck squamous cell carcinoma. Nature Reviews Disease Primers, 2020, 6, 92.	18.1	1,649
4	Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. Cancer Discovery, 2013, 3, 761-769.	7.7	505
5	STAT3 SIGNALING: Anticancer Strategies and Challenges. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 18-26.	3.4	350
6	Characterization of HPV and host genome interactions in primary head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15544-15549.	3.3	317
7	First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. Cancer Discovery, 2012, 2, 694-705.	7.7	260
8	Exome and genome sequencing of nasopharynx cancer identifies NF-Î²B pathway activating mutations. Nature Communications, 2017, 8, 14121.	5.8	227
9	HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. Clinical Cancer Research, 2009, 15, 3740-3750.	3.2	196
10	EGFR-targeted therapies in the post-genomic era. Cancer and Metastasis Reviews, 2017, 36, 463-473.	2.7	182
11	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science Translational Medicine, 2017, 9, .	5.8	174
12	Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nature Genetics, 2016, 48, 1544-1550.	9.4	164
13	The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncology, 2016, 56, 84-92.	0.8	141
14	Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer. Clinical Cancer Research, 2012, 18, 4986-4996.	3.2	135
15	Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2010, 28, 5294-5300.	0.8	132
16	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nature Genetics, 2014, 46, 939-943.	9.4	126
17	Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells. Clinical Cancer Research, 2011, 17, 4425-4438.	3.2	106
18	TGF-Î± and EGFR in head and neck cancer. Journal of Cellular Biochemistry, 1993, 53, 188-191.	1.2	100

#	Article	IF	Citations
19	HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. Annual Review of Medicine, 2016, 67, 91-101.	5.0	97
20	Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opinion on Emerging Drugs, 2010, 15, 355-373.	1.0	96
21	Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection. Molecular Cancer Research, 2014, 12, 571-582.	1.5	94
22	c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. Clinical Cancer Research, 2013, 19, 380-392.	3.2	90
23	Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance. Clinical Cancer Research, 2011, 17, 5935-5944.	3.2	87
24	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1114-1119.	3.3	86
25	To â€œGrowâ€•or â€œGoâ€• TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN. Clinical Cancer Research, 2014, 20, 4673-4688.	3.2	86
26	APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene, 2019, 38, 3475-3487.	2.6	81
27	Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas. Cancer Discovery, 2015, 5, 239-244.	7.7	80
28	Targeting Epidermal Growth Factor Receptor and Src Pathways in Head and Neck Cancer. Seminars in Oncology, 2008, 35, 286-297.	0.8	79
29	HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2015, 21, 526-533.	3.2	77
30	Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prevention Research, 2016, 9, 547-557.	0.7	77
31	HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clinical Cancer Research, 2016, 22, 4005-4013.	3.2	75
32	Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirusâ€“Host Protein Network. Cancer Discovery, 2018, 8, 1474-1489.	7.7	67
33	BET Inhibition Overcomes Receptor Tyrosine Kinaseâ€“Mediated Cetuximab Resistance in HNSCC. Cancer Research, 2018, 78, 4331-4343.	0.4	66
34	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. Journal of Clinical Oncology, 2009, 27, 1235-1242.	0.8	63
35	JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth. Neoplasia, 2015, 17, 256-264.	2.3	59
36	Caspaseâ€8 mutations in head and neck cancer confer resistance to death receptorâ€mediated apoptosis and enhance migration, invasion, and tumor growth. Molecular Oncology, 2014, 8, 1220-1230.	2.1	58

#	Article	IF	Citations
37	Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Molecular Cancer Therapeutics, 2009, 8, 2211-2220.	1.9	56
38	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer, 2013, 13, 602.	1.1	56
39	Inhibition of EGFR-STAT3 Signaling with Erlotinib Prevents Carcinogenesis in a Chemically-Induced Mouse Model of Oral Squamous Cell Carcinoma. Cancer Prevention Research, 2011, 4, 230-237.	0.7	55
40	The non-coding landscape of head and neck squamous cell carcinoma. Oncotarget, 2016, 7, 51211-51222.	0.8	53
41	Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth. Theranostics, 2015, 5, 1378-1387.	4.6	51
42	Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. PLoS ONE, 2015, 10, e0135750.	1.1	51
43	The Fanconi anemia pathway: Repairing the link between DNA damage and squamous cell carcinoma. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2013, 743-744, 78-88.	0.4	50
44	Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery. PLoS ONE, 2014, 9, e102678.	1.1	50
45	Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head and Neck, 2016, 38, 1759-1764.	0.9	50
46	New Therapies in Head and Neck Cancer. Trends in Cancer, 2018, 4, 385-396.	3.8	50
47	Erlotinib, Erlotinibâ€“Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. Clinical Cancer Research, 2014, 20, 3289-3298.	3.2	48
48	Proteomic Characterization of Head and Neck Cancer Patientâ€“Derived Xenografts. Molecular Cancer Research, 2016, 14, 278-286.	1.5	48
49	Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemotherapy and Pharmacology, 2009, 63, 983-995.	1.1	47
50	The RARSâ€“MAD1L1 Fusion Gene Induces Cancer Stem Cellâ€“like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clinical Cancer Research, 2018, 24, 659-673.	3.2	47
51	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. Journal of Experimental Medicine, 2019, 216, 419-427.	4.2	46
52	Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. Clinical Cancer Research, 2015, 21, 4597-4606.	3.2	45
53	Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clinical Cancer Research, 2017, 23, 3072-3083.	3.2	45
54	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight, 2017, 2, e90449.	2.3	45

#	Article	IF	Citations
55	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2015, 1, 238.	3.4	44
56	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opinion on Emerging Drugs, 2018, 23, 283-299.	1.0	44
57	Integration of molecular targeted therapy with radiation in head and neck cancer. , 2014, 142, 88-98.		43
58	Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology, 2013, 7, 344-355.	1.3	39
59	Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs, 2015, 20, 313-329.	1.0	39
60	Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nature Communications, 2021, 12, 2383.	5.8	39
61	The Efficacy of Topical Antibiotic Prophylaxis for Contaminated Head and Neck Surgery. Laryngoscope, 1994, 104, 719???724.	1.1	38
62	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science, 2021, 374, eabf2911.	6.0	37
63	Systemic Administration of a Cyclic Signal Transducer and Activator of Transcription 3 (STAT3) Decoy Oligonucleotide Inhibits Tumor Growth without Inducing Toxicological Effects. Molecular Medicine, 2014, 20, 46-56.	1.9	34
64	MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. BMC Cancer, 2015, 15, 861.	1.1	34
65	ATR inhibition sensitizes HPVâ^' and HPV+ head and neck squamous cell carcinoma to cisplatin. Oral Oncology, 2019, 95, 35-42.	0.8	34
66	Head and Neck Cancer: Table 1. Cancer Research, 2004, 64, 8126-8129.	0.4	33
67	Womenâ€™s Experiences of Promotion and Tenure in Academic Medicine and Potential Implications for Gender Disparities in Career Advancement. JAMA Network Open, 2021, 4, e2125843.	2.8	33
68	Targeting STAT3 in Cancer with Nucleotide Therapeutics. Cancers, 2019, 11, 1681.	1.7	32
69	Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research, 2018, 78, 2383-2395.	0.4	31
70	STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 1917-1926.	1.9	30
71	PD-1⁺CXCR5^{â^'}CD4⁺ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. , 2021, 9, e002101.		30
72	Nucleic acid-based approaches to STAT inhibition. Jak-stat, 2012, 1, 285-291.	2.2	29

#	Article	IF	Citations
73	New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. Clinical Cancer Research, 2016, 22, 4283-4290.	3.2	29
74	High-Content pSTAT3/1 Imaging Assays to Screen for Selective Inhibitors of STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Assay and Drug Development Technologies, 2014, 12, 55-79.	0.6	28
75	Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobialâ€based therapeutics. Periodontology 2000, 2021, 87, 76-93.	6.3	28
76	Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biology and Therapy, 2012, 13, 935-945.	1.5	27
77	Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3581-3585.	1.0	27
78	Quantifying Metabolic Heterogeneity in Head and Neck Tumors in Real Time: 2-DG Uptake Is Highest in Hypoxic Tumor Regions. PLoS ONE, 2014, 9, e102452.	1.1	25
79	NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. Advances in Biological Regulation, 2020, 75, 100653.	1.4	25
80	HCS Campaign to Identify Selective Inhibitors of IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Assay and Drug Development Technologies, 2015, 13, 356-376.	0.6	24
81	Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clinical Cancer Research, 2019, 25, 5752-5758.	3.2	24
82	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. Seminars in Radiation Oncology, 2018, 28, 2-11.	1.0	23
83	Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene, 2019, 38, 1936-1950.	2.6	23
84	STAT3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e81819.	1.1	22
85	Targeting the JAK/STAT pathway in solid tumors. Journal of Cancer Metastasis and Treatment, 2020, 6, .	0.5	21
86	Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncology, 2014, 50, 120-127.	0.8	20
87	A watershed year for improvements in treatment?. Nature Reviews Clinical Oncology, 2017, 14, 76-78.	12.5	20
88	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. Journal of Clinical Investigation, 2021, 131, .	3.9	20
89	Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. Cancers, 2020, 12, 1537.	1.7	19
90	Critical analysis of the potential for targeting STAT3 in human malignancy. OncoTargets and Therapy, 2013, 6, 999.	1.0	18

#	Article	IF	Citations
91	Treatment of Fanconi Anemiaâ€“Associated Head and Neck Cancer: Opportunities to Improve Outcomes. Clinical Cancer Research, 2021, 27, 5168-5187.	3.2	18
92	Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. Molecular Cancer Therapeutics, 2020, 19, 1562-1571.	1.9	17
93	Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2015, 10, e0117781.	1.1	16
94	Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma. Cancer Letters, 2015, 357, 549-556.	3.2	16
95	2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5081-5085.	1.0	15
96	Treatment of head and neck cancer in the elderly. Expert Opinion on Pharmacotherapy, 2016, 17, 1903-1921.	0.9	15
97	Oral Cancer Chemopreventionâ€”The End of EPOC, the Beginning of an Epoch of Molecular Selection. JAMA Oncology, 2016, 2, 178.	3.4	14
98	HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma. Scientific Reports, 2019, 9, 9130.	1.6	14
99	Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opinion on Investigational Drugs, 2019, 28, 351-363.	1.9	14
100	Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118679.	1.9	14
101	CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirusâ€“Associated Head and Neck Cancers. Molecular Cancer Research, 2021, 19, 14-24.	1.5	14
102	Synergistic enhancement by interleukin-1 ? of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Cancer Chemotherapy and Pharmacology, 1993, 32, 339-346.	1.1	13
103	Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma. Cancer Medicine, 2017, 6, 397-407.	1.3	13
104	STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prevention Research, 2016, 9, 657-663.	0.7	12
105	Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. BMC Cancer, 2018, 18, 1107.	1.1	12
106	Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. International Journal of Molecular Sciences, 2018, 19, 1608.	1.8	11
107	Mentoring Relationships and Gender Inequities in Academic Medicine: Findings From a Multi-Institutional Qualitative Study. Academic Medicine, 2022, 97, 136-142.	0.8	11
108	STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors. PLoS ONE, 2020, 15, e0242264.	1.1	11

#	Article	IF	Citations
109	Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. Journal of Chemical Biology, 2017, 10, 129-141.	2.2	10
110	Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides. Molecular Cancer Therapeutics, 2021, 20, 219-228.	1.9	10
111	Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction. Cell Death and Disease, 2021, 12, 775.	2.7	10
112	Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. JCI Insight, 2021, 6, .	2.3	10
113	Spot the difference. Nature, 2017, 541, 162-163.	13.7	9
114	Phase 1 study of EGFRâ€antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Cancer, 2018, 124, 3881-3889.	2.0	8
115	IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer. Cancers, 2021, 13, 2250.	1.7	8
116	MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Oncotarget, 2016, 7, 23300-23311.	0.8	8
117	Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation. Cancer Chemotherapy and Pharmacology, 2016, 78, 1225-1235.	1.1	7
118	PDâ€L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. Head and Neck, 2021, 43, 3364-3373.	0.9	7
119	Established and Emerging Concepts in Epidermal Growth FactorÂReceptor Biology. International Journal of Radiation Oncology Biology Physics, 2007, 69, S22-S24.	0.4	6
120	Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. PLoS ONE, 2020, 15, e0227261.	1.1	6
121	Gene targets of sulforaphane in head and neck squamous cell carcinoma. Molecular Medicine Reports, 2019, 20, 5335-5344.	1.1	6
122	Prognostic biomarkers in patients with human immunodeficiency virusâ€positive disease with head and neck squamous cell carcinoma. Head and Neck, 2017, 39, 2433-2443.	0.9	5
123	Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2014, 32, 6033-6033.	0.8	5
124	Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC).. Journal of Clinical Oncology, 2014, 32, 6090-6090.	0.8	5
125	Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. PLoS ONE, 2016, 11, e0166185.	1.1	4
126	NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models. Cancers, 2022, 14, 506.	1.7	4

#	Article	IF	Citations
127	Head and Neck Cancer among American Indian and Alaska Native Populations in California, 2009â€“2018. Cancers, 2021, 13, 5195.	1.7	3
128	Jak/STAT Signaling in Head and Neck Cancer. Current Cancer Research, 2018, , 155-184.	0.2	3
129	Abstract 4101: Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase inhibitors using an oligonucleotide-based decoy. , 2017, , .		2
130	Networking practices and gender inequities in academic medicine: Women's and men's perspectives. EClinicalMedicine, 2022, 45, 101338.	3.2	2
131	HER2 and HER3 in HPV+ and HPVâ˜ HNSCCâ€"Response. Clinical Cancer Research, 2016, 22, 1826-1826.	3.2	1
132	A Young Man With Chronic Discharge From the Skin of the Lateral Neck. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 99.	1.2	1
133	The Mutational Landscape of Head and Neck Squamous Cell Carcinoma: Opportunities for Detection and Monitoring Via Analysis of Circulating Tumor DNA. , 2021, , 107-122.		1
134	Gender Equity in Science and Medicine: Breaking the Impasse. Cancer Discovery, 2022, 12, 1191-1194.	7.7	1
135	Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy. , 2019, , 1-23.		0
136	Expression of tumor biomarkers in HIV-infected patients with head and neck cancer.. Journal of Clinical Oncology, 2014, 32, 6086-6086.	0.8	0
137	Prevalence and outcome of mutations (mut) in the Fanconi anemia (FA) DNA repair pathway among head and neck cancer (H&N Ca) patients (pts).. Journal of Clinical Oncology, 2014, 32, 6036-6036.	0.8	0
138	A sensible approach to targeting STAT3-mediated transcription. Annals of Translational Medicine, 2016, 4, S57-S57.	0.7	0
139	Title is missing!. , 2020, 15, e0227261.		0
140	Title is missing!. , 2020, 15, e0227261.		0
141	Title is missing!. , 2020, 15, e0227261.		0
142	Title is missing!. , 2020, 15, e0227261.		0